ARTICLE | Clinical News
Thrice-weekly glatiramer regulatory update
September 22, 2014 7:00 AM UTC
Momenta said FDA accepted for review an ANDA for a generic version of thrice-weekly Copaxone glatiramer to treat relapsing forms of multiple sclerosis (MS). Momenta is partnered with Novartis' Sandoz...